Viska Bio
Developer of a modular antibody–enzyme fusion therapeutic platform that targets EGFR‑expressing tumor cells and elicits immunogenic cell death. Primary preclinical program focuses on glioblastoma with a stated path toward IND‑enabling studies in late 2025. Operates from shared laboratory facilities in Cambridge, MA.
Industries
N/A
Products
EGFR‑targeted antibody–xanthine oxidase fusion therapeutic candidate
A fusion therapeutic composed of an EGFR‑binding antibody domain linked to xanthine oxidase intended to kill EGFR‑expressing tumor cells and trigger immunogenic cell death.
EGFR‑targeted antibody–xanthine oxidase fusion therapeutic candidate
A fusion therapeutic composed of an EGFR‑binding antibody domain linked to xanthine oxidase intended to kill EGFR‑expressing tumor cells and trigger immunogenic cell death.
Services
Platform collaboration for target retargeting
Collaborative service to adapt the fusion protein platform to alternative disease targets by exchanging the antibody targeting domain.
Platform collaboration for target retargeting
Collaborative service to adapt the fusion protein platform to alternative disease targets by exchanging the antibody targeting domain.
Expertise Areas
- Immunogenic cell death (ICD)
- Antibody–enzyme fusion therapeutics
- Oncology preclinical development
- EGFR‑targeted therapies
Key Technologies
- Antibody–enzyme fusion proteins
- Antibody targeting to EGFR
- Xanthine oxidase as enzymatic payload
- Assays for ICD biomarkers (calreticulin, HMGB1, extracellular ATP)